Results 211 to 220 of about 26,004 (264)

Prognostic Impact of Unplanned Hospitalization During First-Line Gemcitabine Plus Nab-Paclitaxel Therapy for Unresectable Pancreatic Cancer: A Single-Center Retrospective Observational Study. [PDF]

Cancers (Basel)
Watabe K, Kan M, Ohno I, Uchida S, Sudo T, Yokozuka K, Abe A, Nakaya Y, Ogane Y, Kurosaki H, Sakai M, Sekine Y, Takahashi T, Ouchi M, Ohyama H, Sakai N, Takano S, Takayashiki T, Ohtsuka M, Kato J.   +19 more
europepmc   +1 more source

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. [PDF]

Cell Rep Med
Shi S, Zhang J, Liu R, Gao S, Xu J, Wang W, Wei M, Li J, Liu C, Xu X, Pan W, Tian X, Men L, Wang H, Liang Z, Zhu M, Yang D, Zhai Y, Yu X.   +18 more
europepmc   +1 more source

Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study. [PDF]

Int J Surg
Liang F, Lu G, Sun D, Chen P, Shi Y, Peng H, Zeng T, Hu M, Zhu K, Qiu K, Chen X.   +10 more
europepmc   +1 more source

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 [PDF]

, 2017
Arber, N., Berlin, J. D., Büchler, M. W., Cervantes, A., Ciardiello, F., Dicato, M., Douillard, J. Y., Ducreux, M., Grothey, A., Haller, D., Haustermans, K., Heinemann, V., Hidalgo, M., Labianca, R., Li, J., Marshall, J. L., Nordlinger, B., O'Reilly, E. M., Roth, A., Rougier, P., Ryan, D., Schmiegel, W., Schmoll, H. J., Seufferlein, T., Sobrero, A., Tabernero, J., Tempero, M., Van Cutsem, E., Van Laethem, J. L., Verslype, C., Ychou, M., Zalcberg, J.   +31 more
core  

The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study. [PDF]

J Cancer Res Clin Oncol
Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, Park-Simon TW, Häberle L, Uhrig S, Tome O, Spall T, Theuser AK, Ruebner M, Belleville E, Wallwiener D, Brucker SY, Hartkopf AD.   +17 more
europepmc   +1 more source

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. [PDF]

Redox Biol
Jameson GS, LeGrand SD, Gordon MS, Roe DJ, Wertheim BC, Olszewski K, Rabinowitz J, Evans R, Downes M, Truitt M, Korn R, Han H, Miller RM, Barrett MT, Propper D, Von Hoff DD, Borazanci E.   +16 more
europepmc   +1 more source

Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel. [PDF]

Research (Wash D C)
Yang Q, Mao Y, Han Y, Li K, Hu W, Zhou J, Gong X, Huang S, Zhang R, Liu L, Niu N, Li Y, Ji L, Yi X, Xue W, Ni D, Mao W, Luo P, Luo D, Cheng J.   +19 more
europepmc   +1 more source

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. [PDF]

J Health Econ Outcomes Res
Dennen S, Masek M, Cockrum P, Nagelhout E, Paluri R.   +4 more
europepmc   +1 more source

Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database study in Japan. [PDF]

Int J Clin Oncol
Yuri A, Nakane S, Miyano Y, Yamada K, Sugano H, Nakatsuji E, Aoki M, Murayama A.   +7 more
europepmc   +1 more source

Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study. [PDF]

Ther Adv Med Oncol
Zhou N, Li X, Gao M, Li X, Tan S, Hu Q, Lu Z, Xiao X, Wang T, Zhang S, Luo H, Yi C, Yang Y, Gou H.   +13 more
europepmc   +1 more source